NCT05844293View on ClinicalTrials.gov

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

June 30, 2024

Conditions
FXI
Interventions
DRUG

FXI-GalNAc-siRNA

FXI-GalNAc-siRNA solution for injection

OTHER

Placebo

Saline

Trial Locations (2)

63141

COMPLETED

BioPharma, Creve Coeur

M9L 3A2

RECRUITING

BioPharma, Toronto

Sponsors

Lead Sponsor

Sirnaomics
All Listed Sponsors
lead

Sirnaomics

INDUSTRY

NCT05844293 - Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects | Biotech Hunter | Biotech Hunter